CMR, cardiac magnetic resonance; ECV, extracellular volume fraction; EGE, early gadolinium enhancement; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac event; SSFP, balanced steady state free precession; cardio-oncology; cardiotoxicity; cardiovascular magnetic resonance; chemotherapy; left ventricular dysfunction; tissue characterization
Abstract :
[en] This paper aims to empower and inform cardio-oncologists by providing a practical guide to the clinical application of cardiac magnetic resonance (CMR) in the rapidly evolving field of cardio-oncology. Specifically, we describe how CMR can be used to assess the cardiovascular effects of cancer therapy. The CMR literature, relevant societal guidelines, indication-specific imaging protocols, and methods to overcome some of the challenges encountered in performing and accessing CMR are reviewed.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Harries, Iwan; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR)
Liang, Kate; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR)
Williams, Matthew; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR)
Berlot, Bostjan; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) ; Department of Cardiology, University Medical Centre Ljubljana, Slovenia.
Biglino, Giovanni; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) ; National Heart and Lung Institute, Imperial College London, London, United
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie ; Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.
Plana, Juan Carlos; Texas Heart Institute at Baylor St. Luke's Medical Center, Baylor College of
Bucciarelli-Ducci, Chiara; Bristol Heart Institute, Bristol National Institute of Health Research (NIHR)
Language :
English
Title :
Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review.
Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2768–2801.
Doherty, J.U., Kort, S., Mehran, R., et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. J Am Coll Cardiol 73 (2019), 488–516.
Kramer, C.M., Barkhausen, J., Bucciarelli-Ducci, C., Flamm, S.D., Kim, R.J., Nagel, E., Standardized cardiovascular cardiac magnetic resonance (CMR) protocols: 2020 update. J Cardiovasc Magn Reson, 22, 2020, 17.
Schulz-Menger, J., Bluemke, D.A., Bremerich, J., et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance — 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson, 22, 2020, 19.
Hundley, W.G., Bluemke, D., Bogaert, J.G., et al. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson, 11, 2009, 5.
Dunet, V., Schwitter, J., Meuli, R., Beigelman-Aubry, C., Incidental extracardiac findings on cardiac MR: systematic review and meta-analysis. J Magn Reson Imaging 43 (2016), 929–939.
Grothues, F., Smith, G.C., Moon, J.C., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 (2002), 29–34.
Bellenger, N.G., Burgess, M.I., Ray, S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 21 (2000), 1387–1396.
Mooij, C.F., de Wit, C.J., Graham, D.A., Powell, A.J., Geva, T., Reproducibility of MRI measurements of right ventricular size and function in patients with normal and dilated ventricles. J Magn Reson Imaging 28 (2008), 67–73.
Clarke, C.J., Gurka, M.J., Norton, P.T., Kramer, C.M., Hoyer, A.W., Assessment of the accuracy and reproducibility of RV volume measurements by CMR in congenital heart disease. J Am Coll Cardiol Img 5 (2012), 28–37.
Schulz-Menger, J., Bluemke, D.A., Bremerich, J., et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson, 15, 2013, 35.
Cerqueira, M.D., Weissman, N.J., Dilsizian, V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for health care professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002), 539–542.
Gulati, G., Heck, S.L., Ree, A.H., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37 (2016), 1671–1680.
Pituskin, E., Mackey, J.R., Koshman, S., et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35 (2017), 870–877.
Romano, S., Judd, R.M., Kim, R.J., et al. Association of feature-tracking cardiac magnetic resonance left ventricular global longitudinal strain with all-cause mortality in patients with reduced left ventricular ejection fraction. Circulation 135 (2017), 2313–2315.
Thavendiranathan, P., Poulin, F., Lim, K.D., Plana, J.C., Woo, A., Marwick, T.H., Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63 (2014), 2751–2768.
Negishi, T., Thavendiranathan, P., Negishi, K., Marwick, T.H., Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: the SUCCOUR trial. J Am Coll Cardiol Img 1 (2018), 1098–1105.
Drafts, B.C., Twomley, K.M., D'Agostino, R., et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. J Am Coll Cardiol Img 6 (2013), 877–885.
Jolly, M.P., Jordan, J.H., Meléndez, G.C., McNeal, G.R., D'Agostino, R.B., Hundley, W.G., Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson, 19, 2017, 59.
Ong, G., Brezden-Masley, C., Dhir, V., et al. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol 261 (2018), 228–233.
Erley, J., Genovese, D., Tapaskar, N., et al. Echocardiography and cardiovascular magnetic resonance based evaluation of myocardial strain and relationship with late gadolinium enhancement. J Cardiovasc Magn Reson, 2, 2019, 46.
Ugander, M., Bagi, P.S., Oki, A.J., et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J Am Coll Cardiol Img 5 (2012), 596–603.
Friedrich, M.G., Sechtem, U., Schulz-Menger, J., et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 53 (2009), 1475–1487.
McAlindon, E., Pufulete, M., Lawton, C., Angelini, G.D., Bucciarelli-Ducci, C., Quantification of infarct size and myocardium at risk: evaluation of different techniques and its implications. Eur Heart J Cardiovasc Imaging 16 (2015), 738–746.
Ferreira, V.M., Schulz-Menger, J., Holmvang, G., et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72 (2018), 3158–3176.
Galán-Arriola, C., Lobo, M., Vílchez-Tschischke, J.P., et al. Serial cardiac magnetic resonance to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73 (2019), 779–791.
Haslbauer, J.D., Lindner, S., Valbuena-Lopez, S., et al. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol 275 (2019), 179–186.
Motwani, M., Kidambi, A., Herzog, B.A., Uddin, A., Greenwood, J.P., Plein, S., MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 268 (2013), 26–43.
Wassmuth, R., Lentzsch, S., Erdbruegger, U., et al. Subclinical cardiotoxic effects of anthracyclines as assessed by cardiac magnetic resonance-a pilot study. Am Heart J 141 (2001), 1007–1013.
Kwong, R.Y., Chan, A.K., Brown, K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113 (2006), 2733–2743.
Wu, K.C., Weiss, R.G., Thiemann, D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008), 2414–2421.
O'Hanlon, R., Grasso, A., Roughton, M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56 (2010), 867–874.
Hulten, E., Agarwal, V., Cahill, M., et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging, 9, 2016, e005001.
Gräni, C., Eichhorn, C., Bière, L., et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70 (2017), 1964–1976.
Fontana, M., Pica, S., Reant, P., et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132 (2015), 1570–1579.
Muehlberg, F., Funk, S., Zange, L., et al. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail 5 (2018), 620–629.
Jordan, J.H., D'Agostino, R.B., Hamilton, C.A., et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 7 (2014), 872–879.
Nakano, S., Takahashi, M., Kimura, F., et al. Cardiac magnetic resonance-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: a pilot study to evaluate the feasibility of the method. Cardiol J 23 (2016), 270–280.
Fallah-Rad, N., Walker, J.R., Wassef, A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57 (2011), 2263–2270.
Lunning, M.A., Kutty, S., Rome, E.T., et al. Cardiac magnetic resonance for the assessment of the myocardium after doxorubicin-based chemotherapy. Am J Clin Oncol 38 (2015), 377–381.
Neilan, T.G., Coelho-Filho, O.R., Pena-Herrera, D., et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 110 (2012), 1679–1686.
Lawley, C., Wainwright, C., Segelov, E., Lynch, J., Beith, J., McCrohon, J., Pilot study evaluating the role of cardiac magnetic resonance in monitoring adjuvant trastuzumab therapy for breast cancer. Asia Pac J Clin Oncol 8 (2012), 95–100.
Harries, I., Biglino, G., Baritussio, A., et al. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy. Int J Cardiol 292 (2019), 248–252.
Messroghli, D.R., Moon, J.C., Ferreira, V.M., et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2∗ and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson, 19, 2017, 75.
Miller, C.A., Naish, J.H., Bishop, P., et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 6 (2013), 373–383.
Nakamori, S., Dohi, K., Ishida, M., et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. J Am Coll Cardiol Img 11 (2018), 48–59.
Neilan, T.G., Coelho-Filho, O.R., Shah, R.V., et al. Myocardial extracellular volume by cardiac magnetic resonance in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111 (2013), 717–722.
Jordan, J.H., Vasu, S., Morgan, T.M., et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging, 9, 2016, e004325.
Altaha, M.A., Nolan, M., Marwick, T.H., et al. Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy?: impact of temporal and observer variability. J Am Coll Cardiol Img 13 (2020), 951–962.
Chaosuwannakit, N., D'Agostino, R., Hamilton, C.A., et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28 (2010), 166–172.
Felker, G.M., Thompson, R.E., Hare, J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000), 1077–1084.
Meléndez, G.C., Sukpraphrute, B., D'Agostino, R.B., et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. Am J Cardiol 119 (2017), 1637–1642.
Jordan, J.H., Todd, R.M., Vasu, S., Hundley, W.G., Cardiovascular magnetic resonance in the oncology patient. J Am Coll Cardiol Img 1 (2018), 1150–1172.
Armstrong, G.T., Plana, J.C., Zhang, N., et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance. J Clin Oncol 30 (2012), 2876–2884.
Zamorano, J., An ESC position paper on cardio-oncology. Eur Heart J 37 (2016), 2739–2740.
Ganatra, S., Carver, J.R., Hayek, S.S., et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council Perspectives. J Am Coll Cardiol 74 (2019), 3153–3163.
Kochenderfer, J.N., Somerville, R.P.T., Lu, T., et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T Cells are associated with high serum interleukin-15 levels. J Clin Oncol 35 (2017), 1803–1813.
Burstein, D.S., Maude, S., Grupp, S., Griffis, H., Rossano, J., Lin, K., Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant 2 (2018), 1590–1595.
Ghosh, A., Chen, D., Guha, A., Mackenzie, S., Walker, J.M., Claire, R., CAR T cell therapy–related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?. J Am Coll Cardiol CardioOnc 2 (2020), 97–109.
Ylänen, K., Poutanen, T., Savikurki-Heikkilä, P., Rinta-Kiikka, I., Eerola, A., Vettenranta, K., Cardiac magnetic resonance in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 61 (2013), 1539–1547.
Ylänen, K., Eerola, A., Vettenranta, K., Poutanen, T., Three-dimensional echocardiography and cardiac magnetic resonance in the screening of long-term survivors of childhood cancer after cardiotoxic therapy. Am J Cardiol 113 (2014), 1886–1892.
Chamsi-Pasha, M.A., Zhan, Y., Debs, D., Shah, D.J., CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. J Am Coll Cardiol Img 13:1 Pt 2 (2020), 283–296.
Saiki, H., Petersen, I.A., Scott, C.G., et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135 (2017), 1388–1396.
Ferreira de Souza, T., Quinaglia A C Silva, T., Osorio Costa, F., et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. J Am Coll Cardiol Img 11 (2018), 1045–1055.
Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
Puzanov, I., Diab, A., Abdallah, K., et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5, 2017, 95.
Haanen, J.B.A.G., Carbonnel, F., Robert, C., et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:suppl 4 (2018), iv264–iv266.
Bonaca, M.P., Olenchock, B.A., Salem, J.E., et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140 (2019), 80–91.
Zhang, L., Awadalla, M., Mahmood, S.S., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41 (2020), 1733–1743.
Ederhy, S., Cautela, J., Ancedy, Y., Escudier, M., Thuny, F., Cohen, A., Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. J Am Coll Cardiol Img 11 (2018), 1187–1190.
Cammann, V.L., Sarcon, A., Ding, K.J., et al. Clinical features and outcomes of patients with malignancy and takotsubo syndrome: observations from the International Takotsubo Registry. J Am Heart Assoc, 8, 2019, e010881.
Eitel, I., von Knobelsdorff-Brenkenhoff, F., Bernhardt, P., et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 306 (2011), 277–286.
Montalescot, G., Sechtem, U., Achenbach, S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34 (2013), 2949–3003.
Ibanez, B., James, S., Agewall, S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39 (2018), 119–177.
Dastidar, A.G., Rodrigues, J.C., Baritussio, A., Bucciarelli-Ducci, C., MRI in the assessment of ischaemic heart disease. Heart 102 (2016), 239–252.
Nagel, E., Greenwood, J.P., McCann, G.P., et al. Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380 (2019), 2418–2428.
Kristensen, S.D., Knuuti, J., Saraste, A., et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management [in Polish]. Kardiol Pol 72 (2014), 857–918.
van Nimwegen, F.A., Schaapveld, M., Janus, C.P., et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175 (2015), 1007–1017.
Darby, S.C., Ewertz, M., McGale, P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 (2013), 987–998.
Correa, C.R., Litt, H.I., Hwang, W.T., Ferrari, V.A., Solin, L.J., Harris, E.E., Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25 (2007), 3031–3037.
Machann, W., Beer, M., Breunig, M., et al. Cardiac magnetic resonance findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 79 (2011), 1117–1123.
Tichelli, A., Bucher, C., Rovó, A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 11 (2007), 3463–3471.
Lancellotti, P., Nkomo, V.T., Badano, L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14 (2013), 721–740.
Hull, M.C., Morris, C.G., Pepine, C.J., Mendenhall, N.P., et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290 (2003), 2831–2837.
Maraldo, M.V., Ng, A.K., Minimizing cardiac risks with contemporary radiation therapy for Hodgkin lymphoma. J Clin Oncol 34 (2016), 208–210.
Caruthers, S.D., Lin, S.J., Brown, P., et al. Practical value of cardiac magnetic resonance for clinical quantification of aortic valve stenosis: comparison with echocardiography. Circulation 108 (2003), 2236–2243.
Søndergaard, L., Hildebrandt, P., Lindvig, K., et al. Valve area and cardiac output in aortic stenosis: quantification by magnetic resonance velocity mapping. Am Heart J 126 (1993), 1156–1164.
Piccirillo, J.F., Tierney, R.M., Costas, I., Grove, L., Spitznagel, E.L., Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 (2004), 2441–2447.
Wu, S., Chen, J.J., Kudelka, A., Lu, J., Zhu, X., Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9 (2008), 117–123.
Maceira, A.M., Mohiaddin, R.H., Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson, 14, 2012, 28.
Valent, P., Hadzijusufovic, E., Schernthaner, G.H., Wolf, D., Rea, D., le Coutre, P., Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125 (2015), 901–906.
Fajardo, L.F., Is the pathology of radiation injury different in small vs large blood vessels?. Cardiovasc Radiat Med 1 (1999), 108–110.
Plana, J.C., Galderisi, M., Barac, A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 (2014), 911–939.
Rhodes, M., Lautz, T., Kavanaugh-Mchugh, A., et al. Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients. Bone Marrow Transplant 36 (2005), 139–144.
Bogaert, J., Francone, M., Cardiovascular magnetic resonance in pericardial diseases. J Cardiovasc Magn Reson, 11, 2009, 14.
Kramer, C.M., Barkhausen, J., Flamm, S.D., Kim, R.J., Nagel, E., Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson, 15, 2013, 91.
Hoey, E.T., Gulati, G.S., Ganeshan, A., Watkin, R.W., Simpson, H., Sharma, S., Cardiovascular MRI for assessment of infectious and inflammatory conditions of the heart. AJR Am J Roentgenol 197 (2011), 103–112.
Flett, A.S., Hayward, M.P., Ashworth, M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122 (2010), 138–144.
Karamitsos, T.D., Piechnik, S.K., Banypersad, S.M., et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Img 6 (2013), 488–497.
Banypersad, S.M., Sado, D.M., Flett, A.S., et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6 (2013), 34–39.
Maceira, A.M., Joshi, J., Prasad, S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005), 186–193.
Falk, R.H., Quarta, C.C., Dorbala, S., How to image cardiac amyloidosis. Circ Cardiovasc Imaging 7 (2014), 552–562.
Armenian, S.H., Lacchetti, C., Barac, A., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 (2017), 893–911.
Vermersch, M., Longere, B., Coisne, A., et al. Compressed sensing real-time cine imaging for assessment of ventricular function, volumes and mass in clinical practice. Eur Radiol 30 (2020), 609–619.
Ferrari, V.A., Whitman, B., Blankenship, J.C., et al. Cardiovascular imaging payment and reimbursement systems: understanding the past and present in order to guide the future. J Am Coll Cardiol Img 7 (2014), 324–332.
Garg, R., Sevilla, A., Garberich, R., Fleishman, C.E., Remote delivery of congenital cardiac cardiac magnetic resonance services: a unique telemedicine model. Pediatr Cardiol 36 (2015), 226–232.
Cardinale, D., Colombo, A., Bacchiani, G., et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 (2015), 1981–1988.
Yeh, E.T., Bickford, C.L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 (2009), 2231–2247.
Khakoo, A.Y., Kassiotis, C.M., Tannir, N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112 (2008), 2500–2508.
Cornell, R.F., Ky, B., Weiss, B.M., et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 37 (2019), 1946–1955.
Barthur, A., rezden-Masley, C., Connelly, K.A., et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson, 19, 2017, 44.
Nazarian, S., Hansford, R., Rahsepar, A.A., et al. Safety of cardiac magnetic resonance in patients with cardiac devices. N Engl J Med 377 (2017), 2555–2564.
Marano, A.A., Henderson, P.W., Prince, M.R., Dashnaw, S.M., Rohde, C.H., Effect of MRI on breast tissue expanders and recommendations for safe use. J Plast Reconstr Aesthet Surg 70 (2017), 1702–1707.
Woolen, S.A., Shankar, P.R., Gagnier, J.J., MacEachern, M.P., Singer, L., Davenport, M.S., Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group ii gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med 180 (2019), 223–230.
